AbbVie has broken ground on a $70 million expansion of its AbbVie Bioresearch Center (ABC) in Worcester, Massachusetts, a key hub for the company’s biologics research, development, and manufacturing. The project is part of AbbVie’s broader plan to invest over $10 billion in U.S. operations to support innovation and bolster biologics manufacturing capabilities.
The expansion will significantly increase AbbVie’s domestic production capacity to meet rising global demand for oncology and immunology medicines. It includes new biologics manufacturing areas and a three-story facility featuring laboratories, warehouse space, and offices. The construction will also facilitate the transfer of select oncology products from Europe to the U.S., allowing for faster and more localized production.
Azita Saleki-Gerhardt, Ph.D., AbbVie’s executive vice president and chief operations officer, emphasized the importance of the site, noting that ABC has been a leader in biologics manufacturing for more than 30 years. “This investment will further expand AbbVie’s biologics manufacturing capacity and position ABC to build upon its impressive track record of developing, manufacturing, and launching next-generation complex biologic medicines that improve the lives of millions of patients worldwide,” she said.
AbbVie employs 28,000 people across all 50 states and Puerto Rico, including over 2,000 in Massachusetts. The expansion in Worcester is expected to create additional jobs and strengthen AbbVie’s U.S. manufacturing network, which already supports more than 6,000 jobs across 11 sites.